Figure 7.
Figure 7. The expression of Bcl-XL and Bad phosphorylation contribute to survival function of FLT3/ITD in FLT3/ITD-32D cells. (A) In FLT3/ITD-32D cells, after 24-hour treatment with Bcl-XL/antisense (Bcl-XL/AS) or Bcl-XL/sense (Bcl-XL/S) oligonucleotides and an additional 4-hour treatment with or without kinase inhibitors (10 μM LY294002 [LY] and 10 μM PD98059 [PD]), each sample was lysed and immunoblotted by anti–Bcl-XL antibody. Each cell lysate was immunoprecipitated by anti-Bad antibody and immunoblotted by antiphospho Bad specific antibodies. Immunoblotting by antiactin antibody is for the control of total protein level. (B) Inhibitory effect of Bcl-XL/AS and kinase inhibitors on the viability of FLT3/ITD-32D cells. After 24-hour treatment with each oligonucleotide, LY (10 μM) and PD (10 μM) were or were not applied. The data shown are means and SDs of 3 independent experiments.

The expression of Bcl-XL and Bad phosphorylation contribute to survival function of FLT3/ITD in FLT3/ITD-32D cells. (A) In FLT3/ITD-32D cells, after 24-hour treatment with Bcl-XL/antisense (Bcl-XL/AS) or Bcl-XL/sense (Bcl-XL/S) oligonucleotides and an additional 4-hour treatment with or without kinase inhibitors (10 μM LY294002 [LY] and 10 μM PD98059 [PD]), each sample was lysed and immunoblotted by anti–Bcl-XL antibody. Each cell lysate was immunoprecipitated by anti-Bad antibody and immunoblotted by antiphospho Bad specific antibodies. Immunoblotting by antiactin antibody is for the control of total protein level. (B) Inhibitory effect of Bcl-XL/AS and kinase inhibitors on the viability of FLT3/ITD-32D cells. After 24-hour treatment with each oligonucleotide, LY (10 μM) and PD (10 μM) were or were not applied. The data shown are means and SDs of 3 independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal